TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings

Table 3

Clinical and laboratory features of 97 MPNs patients stratified by TET2 status.

	TET2-positive MPN (𝑛=7)	TET2-negative MPN (𝑛=90)	𝑃 value
Diagnosis
MPN-U (𝑛=8)	3 (37.5%)	5/8 (62.5%)
ET (𝑛=55)	2 (3.6%)	53 (96.4%)	0.005
PV (𝑛=25)	2 (8.0%)	23 (92%)
IMF (𝑛=9)	0	9
Median age, years (range)	71 (43–76)	65.5 (25–89)	0.57
Follow-up months, median (range)	38.6 (13.3–130)	54.2 (4.3–195.7)	0.38
Hb, g/100 mL (range)	16.1 (13.3–19.9)	15.2 (11.1–21.5)	0.22
WBC × 10^9/L (range)	6.86 (5.4–12.4)	8.56 (1.7–19.6)	0.3
Monocytes × 10^9/L (range)	0.3 (0.1–1.15)	0.45 (0.02–0.9)	0.45
Plt × 10^9/L (range)	476 (134–849)	629 (149–1750)	0.02
JAK 2 V617F 𝑛 (%)	6/7 (85.7)	66/90 (73.3)	0.78
JAK 2 V617F burden median % (range)	24 (5–65)	25 (5–90)	0.99
EEC 𝑛 (%)	4/7 (57.1)	71/90 (78.8)	0.39
CFU-MK 𝑛 (%)	1/7 (14.2)	57/90 (63.3)	0.01
CD34 + SP × 10^9/L (range)	0.021 (0.0103–0.273)	0.03 (0.0015–0.61)	0.89
CD34 + SP (%) (range)	0.03 (0.02–0.35)	0.035 (0.0015–0.56)	0.43
Bone marrow cellularity % (range)	50 (30–80)	50 (20–98)	0.96
Single cytogenetic abnormality (𝑛)	0/7	5/90 (5.5)	0.49
Complex karyotype (𝑛)	0/7	1/90 (1.1)
Trisomy (𝑛)	0/7	1/90 (1.1)
Pruritus (𝑛)	2/7	21/90	0.88
Palpable splenomegaly (𝑛)	2/7	37/90	0.8
Splenic square cm^2 (range)	40 (31–105)	42 (25–200)	0.45
Arterial thromboses (𝑛)	1/7	21/90	0.43
Venous thromboses (𝑛)	2/7	7/90
Spontaneous haemorrhage (𝑛)	0/7	2/90	0.58
Posttraumatic haemorrhage (𝑛)	0/7	2/90
Cytoreductive treatment (𝑛)	7/7	86/90	0.66